4.8 Article

Evidence for Delivery of Abraxane via a Denatured-Albumin Transport System

Journal

ACS APPLIED MATERIALS & INTERFACES
Volume 13, Issue 17, Pages 19736-19744

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acsami.1c03065

Keywords

human serum albumin; pancreatic cancer; drug delivery system; denatured albumin; albumin receptor

Funding

  1. Japan Society for the Promotion of Science (JSPS)
  2. Ministry of Education, Culture, Sports, Science and Technology, Japan [18H02587, 15 K08076]
  3. Mishima Kaiun Memorial Foundation
  4. Takahashi Industrial and Economic Research Foundation
  5. Tokushima University
  6. Nagai Foundation
  7. Grants-in-Aid for Scientific Research [18H02587] Funding Source: KAKEN

Ask authors/readers for more resources

Abraxane, an albumin-bound paclitaxel nanoparticle formulation, shows better efficacy against unresectable pancreatic cancer compared to conventional paclitaxel preparations, likely due to its transport through the albumin receptor Gp60. The uptake mechanism of Abraxane is different from that of endogenous albumin, indicating a distinct cellular transport pathway for denatured albumin via gp family proteins.
Abraxane, an albumin-bound paclitaxel nanoparticle formulation, is superior to conventional paclitaxel preparations because it has better efficacy against unresectable pancreatic cancer. Previous reports suggest that this better efficacy of Abraxane than conventional paclitaxel preparation is probably due to its transport through Gp60, an albumin receptor on the surface of vascular endothelial cells. The increased tumor accumulation of Abraxane is also caused by the secreted protein acid and rich in cysteine in the tumor stroma. However, the uptake mechanism of Abraxane remains poorly understood. In this study, we demonstrated that the delivery of Abraxane occurred via different receptor pathways from that of endogenous albumin. Our results showed that the uptake of endogenous albumin was inhibited by a Gp60 pathway inhibitor in the process of endocytosis through endothelial cells or tumor cells. In contrast, the uptake of Abraxane-derived HSA was less affected by the Gp60 pathway inhibitor but significantly reduced by denatured albumin receptor inhibitors. In conclusion, these data indicate that Abraxane-derived HSA was taken up into endothelial cells or tumor cells by a mechanism different from normal endogenous albumin. These new data on distinct cellular transport pathways of denatured albumin via gp family proteins different from those of innate albumin shed light on the mechanisms of tumor delivery and antitumor activity of Abraxane and provide new scientific rationale for the development of a novel albumin drug delivery strategy via a denatured albumin receptor.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available